Janux Therapeutics
JANX
174 hedge funds and large institutions have $1.59B invested in Janux Therapeutics in 2025 Q3 according to their latest regulatory filings, with 22 funds opening new positions, 57 increasing their positions, 64 reducing their positions, and 22 closing their positions.
172% more call options, than puts
Call options by funds: $14.6M | Put options by funds: $5.39M
5% more capital invested
Capital invested by funds: $1.51B → $1.59B (+$79.6M)
0% more funds holding
Funds holding: 174 → 174 (0)
0% more first-time investments, than exits
New positions opened: 22 | Existing positions closed: 22
2.17% less ownership
Funds ownership: 110.61% → 108.44% (-2.2%)
11% less repeat investments, than reductions
Existing positions increased: 57 | Existing positions reduced: 64
40% less funds holding in top 10
Funds holding in top 10: 5 → 3 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Investment Management
Baltimore,
Maryland
|
+$23.7M |
| 2 |
O
OrbiMed
New York
|
+$13.5M |
| 3 |
State Street
Boston,
Massachusetts
|
+$12.3M |
| 4 |
TCM
Tang Capital Management
San Diego,
California
|
+$12.2M |
| 5 |
BlackRock
New York
|
+$7.99M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EC
EcoR1 Capital
San Francisco,
California
|
-$34M |
| 2 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$15.8M |
| 3 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$12.9M |
| 4 |
Point72 Asset Management
Stamford,
Connecticut
|
-$10.6M |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$10.4M |
JANX Hedge Fund Activity: Q3 2025 in Review
174 of the 7,640 institutional investors tracked by Wall St. Rank reported a position in Janux Therapeutics (JANX) for Q3 2025, worth a combined $1.59B — up 5.3% from $1.51B a quarter earlier.
Fund positioning in JANX was balanced in Q3 2025: 22 funds opened new positions, 22 closed out, 57 added to existing stakes and 64 trimmed.
The largest buyer was T. Rowe Price Investment Management, opening a new position worth an estimated $23.7M. The largest seller was EcoR1 Capital, exiting entirely with an estimated $34M sold.
- 174 institutional investors held Janux Therapeutics (JANX) as of Q3 2025, unchanged from Q2 2025.
- Funds reported $1.59B of Janux Therapeutics stock for Q3 2025, up 5.3% quarter-over-quarter.
- 22 funds opened new Janux Therapeutics positions in Q3 2025 and 22 closed out, a net change of 0 holders.
- The largest Janux Therapeutics buyer in Q3 2025 was T. Rowe Price Investment Management, an estimated $23.7M added.
- The largest Janux Therapeutics seller in Q3 2025 was EcoR1 Capital, an estimated $34M sold.
Based on aggregated 13F filings for Q3 2025.